Cargando…
1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection
BACKGROUND: Prosthetic joint infections (PJIs) are serious complications after total joint arthroplasty. Staphylococcus aureus and Staphylococcus epidermidis, which are proficient biofilm-formers, account for ~60% of PJI cases. Therapy often includes rifampin because of its anti-biofilm activity; th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810379/ http://dx.doi.org/10.1093/ofid/ofz360.1450 |
_version_ | 1783462238544199680 |
---|---|
author | Albano, Mariana Karau, Melissa J Osmon, Douglas R Oravec, Caitlin P Abdel, Matthew P Patel, Robin |
author_facet | Albano, Mariana Karau, Melissa J Osmon, Douglas R Oravec, Caitlin P Abdel, Matthew P Patel, Robin |
author_sort | Albano, Mariana |
collection | PubMed |
description | BACKGROUND: Prosthetic joint infections (PJIs) are serious complications after total joint arthroplasty. Staphylococcus aureus and Staphylococcus epidermidis, which are proficient biofilm-formers, account for ~60% of PJI cases. Therapy often includes rifampin because of its anti-biofilm activity; the activity of other rifamycins against staphylococcal biofilms is poorly defined. This study evaluated the in vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against S. aureus and S. epidermidis biofilms formed by isolates from patients with PJI. METHODS: 200 staphylococcal isolates were tested (111 S. aureus and 89 S. epidermidis). All S. aureus isolates, and all except 7 S. epidermidis isolates, were rifampin susceptible. Rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm bactericidal concentration (MBBCs) were determined using a pegged lid microtiter plate assay. RESULTS: Rifampin-resistant isolates had MBICs and MBBCs ≥16 µg/mL. Results for the rifampin-susceptible isolates are shown. All 193 rifampin-susceptible isolates had rifampin MBICs ≤1 µg/mL (rifampin-susceptible breakpoint for planktonic susceptibility testing), with 1, 2, and 2 isolates having MBICs > 1 µg/mL for rifabutin, rifapentine and rifaximin, respectively. S. aureus MBBC(50) values were 8, 1, 2 and 4 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively. S. epidermidis MBBC(50) values were 2, 0.06, 0.25, and 0.5 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively, for rifampin-susceptible isolates. CONCLUSION: Rifabutin and rifapentine, and to a lesser extent, rifaximin, show promising in vitro activity against rifampin-susceptible staphylococcal biofilms formed by isolates associated with PJI; studies evaluating in vivo activity are warranted. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6810379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68103792019-10-28 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection Albano, Mariana Karau, Melissa J Osmon, Douglas R Oravec, Caitlin P Abdel, Matthew P Patel, Robin Open Forum Infect Dis Abstracts BACKGROUND: Prosthetic joint infections (PJIs) are serious complications after total joint arthroplasty. Staphylococcus aureus and Staphylococcus epidermidis, which are proficient biofilm-formers, account for ~60% of PJI cases. Therapy often includes rifampin because of its anti-biofilm activity; the activity of other rifamycins against staphylococcal biofilms is poorly defined. This study evaluated the in vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against S. aureus and S. epidermidis biofilms formed by isolates from patients with PJI. METHODS: 200 staphylococcal isolates were tested (111 S. aureus and 89 S. epidermidis). All S. aureus isolates, and all except 7 S. epidermidis isolates, were rifampin susceptible. Rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm bactericidal concentration (MBBCs) were determined using a pegged lid microtiter plate assay. RESULTS: Rifampin-resistant isolates had MBICs and MBBCs ≥16 µg/mL. Results for the rifampin-susceptible isolates are shown. All 193 rifampin-susceptible isolates had rifampin MBICs ≤1 µg/mL (rifampin-susceptible breakpoint for planktonic susceptibility testing), with 1, 2, and 2 isolates having MBICs > 1 µg/mL for rifabutin, rifapentine and rifaximin, respectively. S. aureus MBBC(50) values were 8, 1, 2 and 4 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively. S. epidermidis MBBC(50) values were 2, 0.06, 0.25, and 0.5 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively, for rifampin-susceptible isolates. CONCLUSION: Rifabutin and rifapentine, and to a lesser extent, rifaximin, show promising in vitro activity against rifampin-susceptible staphylococcal biofilms formed by isolates associated with PJI; studies evaluating in vivo activity are warranted. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810379/ http://dx.doi.org/10.1093/ofid/ofz360.1450 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Albano, Mariana Karau, Melissa J Osmon, Douglas R Oravec, Caitlin P Abdel, Matthew P Patel, Robin 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection |
title | 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection |
title_full | 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection |
title_fullStr | 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection |
title_full_unstemmed | 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection |
title_short | 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection |
title_sort | 1586. in vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against biofilms formed by staphylococci isolated from prosthetic joint infection |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810379/ http://dx.doi.org/10.1093/ofid/ofz360.1450 |
work_keys_str_mv | AT albanomariana 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection AT karaumelissaj 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection AT osmondouglasr 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection AT oraveccaitlinp 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection AT abdelmatthewp 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection AT patelrobin 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection |